Family history, race, and prostate cancer.

Authors

null

Joshua Schiff

Tulane Cancer Center, New Orleans, LA

Joshua Schiff , Elisa M. Ledet , Emma M. Ernst , Cathryn E. Garvey , Patrick Cotogno , Oliver Sartor

Organizations

Tulane Cancer Center, New Orleans, LA, Tulane University School of Medicine, New Orleans, LA, Office of Clinical Research, Tulane Cancer Center, New Orleans, LA

Research Funding

Other

Background: African American (AA) race and family history (FH) of prostate cancer (PCa) increase the incidence and mortality of PCa. The goal of this study was to assess and compare FH in AA and Caucasian (C) men. Methods: During June 2015 through September 2016, 338 men with prostate cancer had FH collected at Tulane Cancer Center (C = 266 and AA = 72). A FH was defined as ≥ 1 1st degree relative with PCa and/or ≥ 2 affected 2nd/3rddegree relatives. Documented clinical factors were age at diagnosis (dx), Gleason score, incidence of radical prostatectomy (RP), and presence of metastases (at any time). Chi-square and Mann-Whitney U tests were performed to identify potential clinical correlates with regard to FH and race. Results: For demographics see table below. On average, men with a FH of PCa (n = 110) had a median age at dx of 59.6 as compared to those without a FH of PCa (n = 151) (median age at dx = 63.0). Overall FH patients (pts) were younger at dx (p = 0.00046). FH had a particularly impactful influence upon the age at dx for C men (p = 0.00086, 58 [n = 88] vs. 62.5 [n = 112]); statistics were limited for AA men. Gleason scores were not different between pts with or without a FH, and there was no relationship between Gleason score and race. Metastatic disease (mets) was detected in 23.97% of men (n = 93). C men with a FH of PCa (n = 40) were 1.55 times more likely to develop mets (p = 0.0352). AA data were limited so no comment can be made. No relationship was detected between the pts having undergone a RP and race, but pts with a FH of PCa (n = 61) were 1.39 times more likely to have undergone surgery (p = 0.016). Data by racial subsets were too limited to be conclusive. Conclusions: The study highlighted the significant impact that FH of PCa has upon age at dx and presence of mets. More AA data are needed to be conclusive.

With FH (n = )Without FH (n = )Total (n = )
AA (n = )264672
C (n = )113153266
Total (n = )139199338

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 225)

DOI

10.1200/JCO.2017.35.6_suppl.225

Abstract #

225

Poster Bd #

J3

Abstract Disclosures

Similar Abstracts

First Author: Nasreen Khan

First Author: Lia DePaula Oliveira

First Author: Edward Christopher Dee

Abstract

2024 ASCO Genitourinary Cancers Symposium

Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC).

First Author: Avina Rami